Patents by Inventor Kristofer Rubin

Kristofer Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
    Publication number: 20070021327
    Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
    Type: Application
    Filed: September 8, 2006
    Publication date: January 25, 2007
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
  • Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
    Patent number: 7141375
    Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: November 28, 2006
    Assignee: Gilead Sciences, Inc.
    Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
  • Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor
    Publication number: 20040224335
    Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
    Type: Application
    Filed: March 2, 2004
    Publication date: November 11, 2004
    Applicant: Gilead Sciences, Inc.
    Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
  • Method for treatment of tumors using nucleic acid ligands to PDGF
    Patent number: 6699843
    Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: March 2, 2004
    Assignee: Gilead Sciences, Inc.
    Inventors: Kristian Pietras, Arne Östman, Carl-Henrik Heldin, Kristofer Rubin
  • Method for treatment of tumors using nucleic acid ligands to PDGF
    Publication number: 20020034506
    Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.
    Type: Application
    Filed: May 17, 2001
    Publication date: March 21, 2002
    Applicant: Gilead Sciences, Inc.
    Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
  • Enhanced anti-cancer agent delivery to solid tumors by primer compounds
    Patent number: 6303660
    Abstract: Primer compositions for anti-cancer agent delivery to solid tumors in mammals, including man, are disclosed. The primer comprise a pharmaceutically acceptable agent which increases the intracellular levels of cyclic adenosine monophosphate (cAMP) in the normal connective tissue cells within solid tumors. Such an agent may be selected from any agents which increase the intracellular levels of cAMP, e.g. agents binding to and stimulating receptors at the connective tissue cell surface within tumors, and agents inhibiting cAMP phosphodiesterase. Local administration of the primer to the solid tumor area results in a lowering of the interstitial pressure. Further, an agent delivery system and a method for delivery of anti-cancer agents to solid tumors are described.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: October 16, 2001
    Assignee: Biophausia AB (publ)
    Inventors: Kristofer Rubin, Mats Sjoquist, Rolf Reed